Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) and PyroGenesis Canada (NASDAQ:PYRGF – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.
Risk and Volatility
Cellectar Biosciences has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, PyroGenesis Canada has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and target prices for Cellectar Biosciences and PyroGenesis Canada, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cellectar Biosciences | 1 | 0 | 3 | 1 | 2.80 |
| PyroGenesis Canada | 0 | 0 | 0 | 0 | 0.00 |
Earnings & Valuation
This table compares Cellectar Biosciences and PyroGenesis Canada”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cellectar Biosciences | N/A | N/A | -$21.79 million | ($3.84) | -0.66 |
| PyroGenesis Canada | $9.14 million | 3.64 | -$21.12 million | ($0.04) | -3.68 |
PyroGenesis Canada has higher revenue and earnings than Cellectar Biosciences. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Cellectar Biosciences and PyroGenesis Canada’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cellectar Biosciences | N/A | -185.35% | -115.42% |
| PyroGenesis Canada | -115.14% | N/A | -60.81% |
Summary
Cellectar Biosciences beats PyroGenesis Canada on 8 of the 14 factors compared between the two stocks.
About Cellectar Biosciences
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
About PyroGenesis Canada
PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
